Sonlicromanol ( DrugBank: Sonlicromanol )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 21 | ミトコンドリア病 | 2 |
21. ミトコンドリア病
臨床試験数 : 33 / 薬物数 : 42 - (DrugBank : 32) / 標的遺伝子数 : 47 - 標的パスウェイ数 : 67
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04846036 (ClinicalTrials.gov) | February 1, 2021 | 5/2/2021 | The KHENERGYC Study | A Randomized Placebo Controlled, Double-blind Phase II Study to Explore the Safety, Efficacy and Pharmacokinetics of Sonlicromanol in Children With Genetically Confirmed Mitochondrial Disease | Mitochondrial Diseases;Mitochondrial DNA tRNALeu(UUR) m.3243A | Drug: Sonlicromanol;Drug: Placebo | Khondrion BV | Julius Clinical, The Netherlands;ProPharma Group;Europees Fonds voor Regionale Ontwikkeling (EFRO);Ardena;Certara | Recruiting | N/A | 17 Years | All | 24 | Phase 2 | Netherlands |
| 2 | EUCTR2020-003124-16-NL (EUCTR) | 12/01/2021 | 20/10/2020 | The KHENERGYC study: a placebo controlled, double-blind study to explore the safety, efficacy and pharmacokinetics of sonlicromanol in children with a mitochondrial disease. | A randomized placebo controlled, double-blind phase II study to explore the safety, efficacy and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease. | Genetically confirmed mitochondrial disease;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: Sonlicromanol Product Code: KH176 INN or Proposed INN: sonlicromanol Other descriptive name: KH176 | Khondrion B.V. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 24 | Phase 2 | Netherlands |